Frank J. Dixon, A Lifetime of Achievement
1920 - 2008
SAMUEL STROBER, M.D., CHAIRMAN
Professor of Medicine, Division of Immunology and Rheumatology
Stanford University School of Medicine
Dr. Strober has served as Professor of Medicine at Stanford University School of Medicine, Division of Immunology and Rheumatology, since 1982. He held the position of Chief of that division from 1978 to 1997, having first arrived at the School of Medicine as a Senior Assistant Resident in 1970. He has been President of the Clinical Immunology Society, and is co-founder of two biotechnology companies.
Dr. Strober's research has focused on the immune cell interactions that prevent graft versus host disease and retain graft anti-tumor activity after bone marrow transplantation, as well as cell interactions that prevent rejection of organ transplants in the absence of immunosuppressive drugs. He is also interested in the pathogenesis of systemic lupus erythematosus, a disease in which the immune system causes excessive inflammation leading to the damage of multiple organs. Throughout his career, Dr. Strober has published over 300 peer-reviewed articles in scientific journals, and has served on editorial boards of immunology journals.
Dr. Strober received his B.A. from Columbia University and his M.D. from Harvard University. He completed fellowships in the Surgical Research Laboratory at the Peter Bent Brigham Hospital in Boston, and in the Sir William Dunn School of Pathology in Oxford University followed by an internship in medicine at Massachusetts General Hospital. Prior to joining Stanford, Dr. Strober completed additional postdoctoral training as a Research Associate in the Laboratory of Cell Biology of the National Cancer Institute, Bethesda.
HAROLD G. BUCHANAN, II
Managing Partner, CE2 Capital Partners
Mr.
Buchanan is a Managing Partner of CE2 Capital Partners, an asset
management firm based in San Diego that invests in environmental
markets and assets that reduce carbon emissions throughout the world.
He is also CEO of CE2 Carbon Capital. Prior to launching the firm,
Mr. Buchanan spent 18 years in the energy industry, serving in various
management and executive positions at three of the nation's largest
energy firms including most recently Senior Vice President of Sempra
Energy in San Diego.
Mr. Buchanan holds an M.B.A from the Massachusetts Institute of
Technology's Sloan School of Management where he was a Sloan Fellow.
He also holds a degree in Finance from the Fisher College of Business
at The Ohio State University. He serves as a guest lecturer at Fisher,
giving talks on topics such as finance, strategy, ethics and corporate
governance and is a member of the school's Committee of Curriculum
Advisors to the Chairman.
NABIL HANNA, Ph.D.
Retired Executive Vice President of Research and Chief Scientific Officer
Biogen IDEC, Inc.
Dr. Hanna is a highly recognized scientist and retired executive from Biogen IDEC Inc. in San Diego, a pharmaceutical development company. During his 14 years there, he led the company's Research and Preclinical Development division, serving as its Chief Scientific Officer and Senior Vice President. He led a research team through the discovery and pre-clinical development of Rituximab and Zevalin, two antibodies now approved for therapy of B cell lymphoma.
With a career spanning more than 30 years, Dr. Hanna's research has focused on developing immunotherapies for the treatment of cancer and autoimmune diseases. He started his career as a postdoctoral fellow at the Tufts Medical School in Boston and later was a researcher at the Hebrew University Medical School in Israel and the NCI-Frederick Cancer Research Center. He joined SmithKline Beecham Pharmaceuticals in 1981 and directed various immunology research programs during his nine years there.
Dr. Hanna received his B.S. and M.S. degrees in Microbiology and his Ph.D. in Immunology from Hebrew University of Jerusalem in Israel. He co-authored more than 120 publications and is a co-inventor of 23 patents, has served as an associate editor for two scientific journals, Cancer Research and Natural Immunity and Cell Growth Regulation, and co-authored the book, "Host Defenses and Immunomodulation to Intracellular Pathogens." He belongs to several professional organizations, and has served on various scientific advisory boards.
MITCHELL KRONENBERG, Ph.D.
President and Scientific Director
La Jolla Institute for Allergy & Immunology
Mitchell Kronenberg was appointed President of La Jolla Institute for Allergy & Immunology in September 2003. He is responsible for the overall administration of physical resources, finances and space at the Institute, and works with the Institute's board of directors, faculty, and executive management to develop and implement strategic plans for shaping the Institute's future.
In addition to his duties as LIAI's chief executive officer, Dr. Kronenberg serves as Scientific Director of the Institute and Head of the Division of Developmental Immunology. He conducts an active research program on the development of the immune system and the pathogenesis of autoimmune disease, and is a world-renowned expert in the field of mucosal and innate immunity.
Dr. Kronenberg graduated with a bachelor's degree in biochemistry from Columbia University, and earned his Ph.D. from the California Institute of Technology (Caltech) in 1983. He stayed on at Caltech as a postdoctoral fellow, and joined the faculty of the UCLA School of Medicine in 1986, serving first as Assistant, and later as Associate and full Professor. In 1997, he moved to La Jolla Institute for Allergy & Immunology
to head the Division of Developmental Immunology. He also is an Adjunct Professor of Biology at the University of California, San Diego.
Dr. Kronenberg is the co-author of more than 225 scientific publications, and according to the Institute for Scientific Information, he is one of the most highly cited scientists in the field of immunology. Dr. Kronenberg has been consistently well funded by the National Institutes of Health (NIH) for more than 20 years, and currently is the principal investigator on five NIH research grants, including an NIH MERIT award. He has been on a number of grant review panels for NIH and private medical research agencies, and has served or is serving on the editorial board of seven scientific journals. He is the winner of the Richard Dwyer award for cancer research (UCLA) and has been the Kroc Professor of Medicine at the University of California, Davis, and the Wellcome Foundation visiting Professor at Harvard University.
TOSHIFUMI MIKAYAMA, Ph.D.
Director of the Board, Executive Officer & Vice President
Kirin Pharma Co., Ltd., Japan
Dr. Mikayama is Executive Officer and Vice President of Kirin Pharma
Co., Ltd. in Tokyo, and Director of Kirin Pharma's Board of Directors.
He joined Kirin Applied Bioscience Lab in 1983 as a Research Scientist,
and became Manager of the Pharmaceutical Research Laboratory in 1994.
One of Kirin's three primary pharmaceutical interests is in immune
system diseases, focusing specifically on the development of advanced
pharmaceutical products involving human antibodies and cell therapy.
Dr. Mikayama received his B.S., M.S. and Ph.D. degrees in Biophysics
and Biochemistry from Tokyo University, Japan. He served as Senior Vice President and Chief Scientific Officer for
Gemini Science Inc. (now Kirin Pharma USA Inc.) from 1998 to 2002, and
then served as Vice President and Scientific Director for Kirin Brewery
Co. Ltd. in Gunma, Japan until 2007.
STEVEN M. ODRE
Adjunct Professor, Intellectual Property
IIT-Chicago Kent School of Law
Steven
Odre joined the La Jolla Institute for Allergy & Immunology in
November 2007. He is currently a consultant for Amgen, Inc. having
retired from Amgen after an almost twenty-year career with the company,
most recently as Sr. Vice President, General Counsel, and Secretary.
Previous to joining Amgen, Mr. Odre was Corporate Patent Counsel at
G.D. Searle in Skokie Ill., and previous to that, he was Division
Patent Counsel at Abbott Labs.
Mr. Odre received his law degree from the Chicago Kent School of Law after spending four years as a chemist. He received his M.S. in Analytical Chemistry from Purdue University and his B.S. in Chemistry from Union College in Schenectady NY. Mr. Odre currently serves on the Union College Board of Trustees, the IIT-Chicago Kent School of Law Board of Overseers and is Adjunct Professor, Intellectual Property at the IIT-Chicago Kent School of Law.
SUSAN L. SWAIN, Ph.D.
President Emeritus, Trudeau Institute
Dr. Swain was appointed to the National Advisory Council on Aging (NACA) in January, 2008, an advisory group to the National Institute on Aging (NIA), part of the department's National Institutes of Health (NIH), on the conduct and support of biomedical, social, and behavioral research on the diseases and conditions associated with aging. Swain is current President Emeritus and former President and Director of the Trudeau Institute in Saranac Lake, N.Y., an independent immunology research center in New York. The Trudeau Institute's research focuses on the body's immune system and response to infectious disease. The studies endeavor to discover how to strengthen vaccines and ongoing immune response functions to fight pandemic influenza, tuberculosis, cancer, AIDS-related infections and other life-threatening infectious diseases.
Dr. Swain holds a Ph.D. in Immunology from Harvard Medical School and a B.A. in Biology from Oberlin College in Ohio. She was a Postdoctoral Fellow at the University of California, San Diego (UCSD) in the Department of Biology and went on to become a UCSD Associate Professor of Biology and Professor of Biology.
Dr. Swain has served as an associate editor for various scientific publications, including the Journal of Experimental Medicine and the Journal of Immunology and also sat on the editorial boards of Cellular Immunology, Cell and Lymphokines. She was elected president of the American Association of Immunologists (AAI) in 2004 and currently serves on the AAI council. She has also served on numerous advisory boards including the Arthritis Foundation's Cellular Immunology Review Panel and the National Institutes of Health (NIH) AIDS Research Advisory Committee. Dr. Swain received the NIH Merit Award in 1996 and in 2005 and was named a New York State Woman of Distinction in 2002. She has organized several international and national meetings and has published 170 scientific papers.
KIMISHIGE ISHIZAKA, M.D., Ph.D.
President and Director Emeritus
La Jolla Institute for Allergy & Immunology
In 1989, Dr. Ishizaka joined La Jolla Institute for Allergy & Immunology
as the Institute's first Scientific Director, and was elected to the additional office of President in 1991, serving in this dual role until his retirement in 1996. He is currently President Emeritus of LIAI.
Dr. Ishizaka and his wife Dr. Teruko Ishizaka received worldwide recognition in 1966 for their discovery of immunoglobulin E (IgE), an antibody contributing to allergic disease. Dr. Ishizaka accomplished this pioneering research while on the faculty of the Department of Microbiology at the University of Colorado Medical School, where he was first appointed Assistant Professor in 1962. He left Colorado for Johns Hopkins University in 1970, serving on the faculty of the School of Medicine and the Faculty of Arts and Science for nearly two decades.
Dr. Ishizaka received his M.D. and Ph.D. in immunology from the University of Tokyo. In the U.S., he undertook postdoctoral training in immunochemistry at the California Institute of Technology (Caltech), and in immunology at The Johns Hopkins University School of Hygiene and Public Health.
Dr. Ishizaka has received numerous national and international awards for his scientific achievements, including his 1983 election to the National Academy of Sciences, the 1985 American College of Physicians Award for Achievement in Medical Science, and the 2000 Japan Prize from the Science and Technology Foundation of Japan. He also served as President of the American Association of Immunologists (1984-85).
FRANK J. DIXON, M.D. 1920-2008
Director Emeritus
The Scripps Research Institute
Dr. Dixon was a founding board member of LIAI and served on the Institute's Board of Directors for 16 years, 14 of those as Chairman. He retired from the La Jolla Institute for Allergy & Immunology's Board in 2005, at which time he was appointed Director Emeritus of the Institute. A renowned leader in the scientific community, Dr. Dixon was a member of the prestigious National Academy of Sciences. Read more
